Suppression of PMA-induced tumor cell invasion by dihydroartemisinin via inhibition of PKCα/Raf/MAPKs and NF-κB/AP-1-dependent mechanisms

Biochemical Pharmacology

Volumn 79, Issue 12, 2010, Pages 1714-1726

  Hwang, Yong Pil ^a   Yun, Hyo Jeong ^a,b   Kim, Hyung Gyun ^a   Han, Eun Hee ^a   Lee, Gye Won ^c   Jeong, Hye Gwang ^a  

^a Chungnam National University   (South Korea)

^b Chosun University   (South Korea)

^c Konyang University   (South Korea)

Author keywords

Antitumor activity; Dihydroartemisinin; Invasion; Matrix metalloproteinases 9; PKC

Indexed keywords

DIHYDROARTEMISININ; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIX METALLOPROTEINASE 14; MITOGEN ACTIVATED PROTEIN KINASE; PHORBOL 13 ACETATE 12 MYRISTATE; PROTEIN C JUN; PROTEIN KINASE C ALPHA; RAF PROTEIN; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSCRIPTION FACTOR AP 1;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME PHOSPHORYLATION; FIBROSARCOMA; HUMAN; HUMAN CELL; PRIORITY JOURNAL;

ARTEMISININS; CELL LINE, TUMOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MAP KINASE KINASE 4; MATRIX METALLOPROTEINASE 2; MATRIX METALLOPROTEINASE 9; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; MOLECULAR STRUCTURE; NF-KAPPA B; PROTEIN KINASE C-ALPHA; RAF KINASES; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTOR AP-1;

EID: 77951298166     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bcp.2010.02.003     Document Type: Article

References (53)

1. Meshnick S.R. Artemisinin: mechanisms of action, resistance and toxicity. Int J Parasitol 2002, 32:1655-1660.
2. O'Neill P.M., Posner G.H. A medicinal chemistry perspective on artemisinin and related endoperoxides. J Med Chem 2004, 47:2945-2964.
3. Dhingra V., Vishweshwar R.K., Lakshmi N.M. Current status of artemisinin and its derivatives as antimalarial drugs. Life Sci 2000, 66:279-300.
4. Efferth T., Dunstan H., Sauerbrey A. The anti-malarial artesunate is also active against cancer. Int J Oncol 2006, 18:767-773.
5. Nam W., Tak J., Ryu J.K. Effects of artemisinin and its derivatives on growth inhibition and apoptosis of oral cancer cells. Head Neck 2007, 29:335-340.
6. Moore J.C., Lai H.C., Li J.R. Oral administration of dihydroartemisinin and ferrous sulfate retarded implanted fibrosarcoma growth in the rat. Cancer Lett 1995, 98:83-87.
7. Disbrow G.L., Baege A.C., Kierpiec K.A. Dihydroartemisinin is cytotoxic to papillomavirus-expressing epithelial cells in vitro and in vivo. Cancer Res 2005, 65:10854-10861.
8. Lai H.C., Singh N.P. Oral artemisinin prevents and delays the development of 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer in the rat. Cancer Lett 2006, 231:43-48.
9. Singh N.P., Lai H.C. Artemisinin induces apoptosis in human cancer cells. Anticancer Res 2004, 24:2277-2280.
10. Lee J., Zhou H.J., Wu X.H. Dihydroartemisinin downregulates vascular endothelial growth factor (VEGF) expression and induces apoptosis in chronic myeloid leukemia K562 cells. Cancer Chemother Pharmaol 2006, 57:213-220.
11. Chen T., Li M., Zhang R., Wang H. Dihydroartemisinin induces apoptosis and sensitizes human ovarian cancer cell. J Cell Mol Med 2009, 13:1358-1370.
12. Jiao Y., Ge C.M., Meng Q.H. Dihydroartemisinin is an inhibitor of ovarian cancer cell growth. Acta Pharmacol Sin 2007, 28:1045-1056.
13. Singh N.P., Lai H. Selective toxicity of dihydroartemisinin and holotransferrin toward human breast cancer cells. Life Sci 2001, 70:49-56.
14. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol 2000, 10:415-433.
15. Liotta L.A., Steeg P.S., Stetler-Stevenson W.G. Cancer metastasis and angiogenesis: an imbalance of positive and negative regulation. Cell 1991, 64:327-336.
16. Deryugina E.I., Luo G.X., Reisfeld R.A., Bourdon M.A., Strongin A. Tumor cell invasion through matrigel is regulated by activated matrix metalloproteinase-2. Anticancer Res 1997, 17:3201-3210.
17. Johnson L.L., Dyer R., Hupe D.J. Matrix metalloproteinases. Curr Opin Chem Biol 1998, 2:466-471.
18. Westermarck J., Kahari V.M. Regulation of matrix metalloproteinase expression in tumor invasion. FASEB J 1999, 13:781-792.
19. Salo T., Mäkelä M., Kylmäniemi M., Autio-Harmainen H., Larjava H. Expression of matrix metalloproteinase-2 and -9 during early human wound healing. Lab Invest 1994, 70:176-182.
20. Liabakk N.B., Talbot I., Smith R.A., Wilkinson K., Balkwill F. Matrix metalloprotease 2 (MMP-2) and matrix metalloprotease 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Res 1996, 56:190-196.
21. Cho H.J., Kang J.H., Kwak J.Y., Lee T.S., Lee I.S., Park N.G., et al. Ascofuranone suppresses PMA-mediated matrix metalloproteinase-9 gene activation through the Ras/Raf/MEK/ERK- and Ap1-dependent mechanisms. Carcinogenesis 2007, 28:1104-1110.
22. Kajanne R., Miettinen P., Mehlem A., Leivonen S.K., Birrer M., Foschi M., et al. EGF-R regulates MMP function in fibroblasts through MAPK and AP-1 pathways. J Cell Physiol 2007, 212:489-497.
23. Srivastava S.K., Jha A., Agarwal S.K., Mukherjee R., Burman A.C. Synthesis and structure-activity relationships of potent antitumor active quinoline and naphthyridine derivatives. Anticancer Agents Med Chem 2007, 7:685-709.
24. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2002, 2:161-174.
25. Forget M.A., Desrosiers R.R., Beliveau R. Physiological roles of matrix metalloproteinases: implications for tumor growth and metastasis. Can J Physiol Pharmacol 1999, 77:465-480.
26. Visse R., Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res 2003, 92:827-839.
27. Kim D., Kim S., Koh H., Yoon S.O., Chung A.S., Cho K.S., et al. Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production. FASEB J 2001, 15:1953-1962.
28. Sato T., Koike L., Miyata Y., Hirata M., Mimaki Y., Sashida Y., et al. Inhibition of activator protein-1 binding activity and phosphatidylinositol 3-kinase pathway by nobiletin, a polymethoxy flavonoid, results in augmentation of tissue inhibitor of metalloproteinases-1 production and suppression of production of matrix metalloproteinases-1 and -9 in human fibrosarcoma HT-1080 cells. Cancer Res 2002, 62:1025-1029.
29. Shin Y., Yoon S.H., Choe E.Y., Cho S.H., Woo C.H., Rho J.Y., et al. PMA-induced up-regulation of MMP-9 is regulated by a PKCalpha-NF-kappaB cascade in human lung epithelial cells. Exp Mol Med 2007, 39:97-105.
30. Eberhardt W., Huwiler A., Beck K.F., Walpen S., Pfeilschifter J. Amplification of IL-1 beta-induced matrix metalloproteinase-9 expression by superoxide in rat glomerular mesangial cells is mediated by increased activities of NF-kappa B and activating protein-1 and involves activation of the mitogen-activated protein kinase pathways. J Immunol 2000, 165:5788-5797.
31. Chung T.W., Moon S.K., Chang Y.C., Ko J.H., Lee Y.C., Cho G., et al. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism. FASEB J 2004, 18:1123-1125.
32. Garg A., Aggarwal B.B. Nuclear transcription factor-κB as a target for cancer drug development. Leukemia 2002, 16:1053-1068.
33. Pastore S., Mascia F., Mariotti F., Dattilo C., Mariani V., Girolomoni G. ERK1/2 regulates epidermal chemokine expression and skin inflammation. J Immunol 2005, 174:5047-5056.
34. Garcia J., Lemercier B., Roman-Roman S., Rawadi G. A mycoplasma fermentans-derived synthetic lipopeptide induces AP-1 and NF-kappaB activity and cytokine secretion in macrophages via the activation of mitogen-activated protein kinase pathways. J Biol Chem 1998, 273:34391-34398.
35. Jung Y.D., Fan F., McConkey D.J., Jean M.E., Liu W., Reinmuth N., et al. Role of P38 MAPK, AP-1, and NF-kappaB in interleukin-1beta-induced IL-8 expression in human vascular smooth muscle cells. Cytokine 2002, 18:206-213.
36. Lee S.O., Jeong Y.J., Im H.G., Kim C.H., Chang Y.C., Lee I.S. Silibinin suppresses PMA-induced MMP-9 expression by blocking the AP-1 activation via MAPK signaling pathways in MCF-7 human breast carcinoma cells. Biochem Biophys Res Commun 2007, 354:165-171.
37. Eberhardt W., Schulze M., Engels C., Klasmeier E., Pfeilschifter J. Glucocorticoid-mediated suppression of cytokine-induced matrix metalloproteinase-9 expression in rat mesangial cells: involvement of nuclear factor-kappaB and Ets transcription factors. Mol Endocrinol 2002, 16:1752-1766.
38. Ma Z., Chang M.J., Shah R., Adamski J., Zhao X., Benveniste E.N. Brg-1 is required for maximal transcription of the human matrix metalloproteinase-2 gene. J Biol Chem 2004, 279:46326-46334.
39. Nabeshima K., Inoue T., Shimao Y., Sameshima T. Matrix metalloproteinases in tumor invasion: role for cell migration. Pathol Int 2002, 52:255-264.
40. Kazes I., Elalamy I., Sraer J.D., Hatmi M., Nguyen G. Platelet release of trimolecular complex components MT1-MMP/TIMP2/MMP2: involvement in MMP2 activation and platelet aggregation. Blood 2000, 96:3064-3069.
41. Eferl R., Wagner E.F. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer 2003, 3:859-868.
42. Karin M., Greten F.R. NF-κB: linking inflammation and immunity to cancer development and progression. Nat Rev Immunol 2005, 5:749-759.
43. Shin H.M., Kim M.H., Kim B.H., Jung S.H., Kim Y.S., Park H.J., et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-kappaB without affecting IkappaB degradation. FEBS Lett 2004, 571:50-54.
44. Wang H.H., Hsieh H.L., Wu C.Y., Sun C.C., Yang C.M. Oxidized low-density lipoprotein induces matrix metalloproteinase-9 expression via a p42/p44 and JNK-dependent AP-1 pathway in brain astrocytes. Glia 2009, 57:24-38.
45. Zhang J. Protein kinase C (PKC) betaII induces cell invasion through a Ras/Mek-, PKC iota/Rac 1-dependent signaling pathway. J Biol Chem 2004, 279:22118-22123.
46. Nguyen M., Arkell J., Jackson C.J. Activated protein C directly activates human endothelial gelatinase A. J Biol Chem 2000, 275:9095-9098.
47. Chen H.H., Zhou H.J., Fang X. Inhibition of human cancer cell line growth and human umbilical vein endothelial cell angiogenesis by artemisinin derivatives in vitro. Pharmacol Res 2003, 48:231-236.
48. Wang J., Guo Y., Zhang B.C., Chen Z.T., Gao J.F. Induction of apoptosis and inhibition of cell migration and tube-like formation by dihydroartemisinin in murine lymphatic endothelial cells. Pharmacology 2007, 80:207-218.
49. Buommino E., Baroni A., Canozo N., Petrazzuolo M., Nicoletti R., Vozza A., et al. Artemisinin reduces human melanoma cell migration by down-regulating alpha V beta 3 integrin and reducing metalloproteinase 2 production. Invest New Drugs 2009, 27:412-418.
50. Park M.J., Park I.C., Hur J.H., Rhee C.H., Choe T.B., Yi D.H., et al. Protein kinase C activation by phorbol ester increases in vitro invasion through regulation of matrix metalloproteinases/tissue inhibitors of metalloproteinases system in D54 human glioblastoma cells. Neurosci Lett 2000, 290:201-204.
51. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., et al. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature 1994, 370:61-65.
52. Woo J.H., Lim J.H., Kim Y.H., Suh S.I., Min D.S., Chang J.S., et al. Resveratrol inhibits phorbol myristate acetate-induced matrix metalloproteinase-9 expression by inhibiting JNK and PKC delta signal transduction. Oncogene 2004, 23:1845-1853.
53. Johnson M.R., Wang K., Smith J.B., Heslin M.J., Diasio R.B. Quantitation of dihydropyrimidine dehydrogenase expression by real-time reverse transcription polymerase chain reaction. Anal Biochem 2000, 278:175-184.